US Pharma MarketingJ&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win
J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win is a pharma and life sciences industry update from FiercePharma. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Johnson & Johnson has unveiled data from a pivotal phase 2/3 trial which could pave the way for a label expansion for Imaavy to become the first approved treatment for warm autoimmune hemolytic anemia.
Source: FiercePharma